116 related articles for article (PubMed ID: 2155065)
1. The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice.
Goddard PM; Jones M; Pollard LA; Valenti MR; Harrap KR
Cancer Chemother Pharmacol; 1990; 25(5):377-9. PubMed ID: 2155065
[TBL] [Abstract][Full Text] [Related]
2. The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin.
Carmichael J; Cantwell BM; Edwards CM; Rapeport WG; Harris AL
BMJ; 1988 Jul; 297(6641):110-1. PubMed ID: 2841996
[No Abstract] [Full Text] [Related]
3. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
4. [BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].
Joss R; Rohrbach D; Buser K; Pirovino M; Karde C; Brunner K
Schweiz Med Wochenschr; 1989 Jun; 119(23):831-4. PubMed ID: 2549616
[TBL] [Abstract][Full Text] [Related]
5. First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache.
Couturier EG; Hering R; Foster CA; Steiner TJ; Clifford Rose F
Headache; 1991 May; 31(5):296-7. PubMed ID: 1650335
[TBL] [Abstract][Full Text] [Related]
6. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Addelman M; Erlichman C; Fine S; Warr D; Murray C
J Clin Oncol; 1990 Feb; 8(2):337-41. PubMed ID: 2153767
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
Bremer K; Uhlenbusch R
Dtsch Med Wochenschr; 1991 Nov; 116(48):1817-23. PubMed ID: 1659980
[TBL] [Abstract][Full Text] [Related]
9. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note.
Goddard PM; Valenti MR; Harrap KR
Ann Oncol; 1991 Sep; 2(8):535-40. PubMed ID: 1793720
[TBL] [Abstract][Full Text] [Related]
10. BRL 43694.
Cancer Invest; 1989; 7(5):535. PubMed ID: 2559785
[No Abstract] [Full Text] [Related]
11. Platinum coordination complexes which circumvent cisplatin resistance.
Harrap KR; Kelland LR; Jones M; Goddard PM; Orr RM; Morgan SE; Murrer BA; Abrams MJ; Giandomenico CM; Cobbleigh T
Adv Enzyme Regul; 1991; 31():31-43. PubMed ID: 1877393
[TBL] [Abstract][Full Text] [Related]
12. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
Plosker GL; Goa KL
Drugs; 1991 Nov; 42(5):805-24. PubMed ID: 1723376
[TBL] [Abstract][Full Text] [Related]
13. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.
Bermudez J; Boyle EA; Miner WD; Sanger GJ
Br J Cancer; 1988 Nov; 58(5):644-50. PubMed ID: 2851311
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response.
Carmichael J; Cantwell BM; Edwards CM; Zussman BD; Thompson S; Rapeport WG; Harris AL
Cancer Chemother Pharmacol; 1989; 24(1):45-9. PubMed ID: 2541937
[TBL] [Abstract][Full Text] [Related]
15. Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.
Hunter AE; Prentice HG; Pothecary K; Coumar A; Collis C; Upward J; Murdoch R; Gandhi L; Hamon M; Butler M
Bone Marrow Transplant; 1991 Jun; 7(6):439-41. PubMed ID: 1651794
[TBL] [Abstract][Full Text] [Related]
16. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients.
Lemerle J; Amaral D; Southall DP; Upward J; Murdoch RD
Eur J Cancer; 1991; 27(9):1081-3. PubMed ID: 1659848
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694).
Reynolds DJ; Barber NA; Grahame-Smith DG; Leslie RA
Brain Res; 1991 Nov; 565(2):231-6. PubMed ID: 1668810
[TBL] [Abstract][Full Text] [Related]
19. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
Warr D; Willan A; Fine S; Wilson K; Davis A; Erlichman C; Rusthoven J; Lofters W; Osoba D; Laberge F
J Natl Cancer Inst; 1991 Aug; 83(16):1169-73. PubMed ID: 1653363
[TBL] [Abstract][Full Text] [Related]
20. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
Soukop M
Eur J Cancer; 1990; 26 Suppl 1():S15-9. PubMed ID: 2169779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
